AU Patent

AU2017205693B2 — Controlled-release CNP agonists with low initial NPR-B activity

Assigned to Ascendis Pharma Endocrinology Division AS · Expires 2022-03-31 · 4y expired

What this patent protects

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC

USPTO Abstract

The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC

Drugs covered by this patent

Patent Metadata

Patent number: AU2017205693B2
Jurisdiction: AU
Classification: —
Expires: 2022-03-31
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Endocrinology Division AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.